Rubicon Research Ltd

Symbol: RUBI

Rubicon Research Pvt. Ltd. is a Mumbai-based specialty pharmaceutical company that focuses on developing complex and value-added drug products for a global clientele. Rather than discovering new drugs, Rubicon leverages its proprietary drug delivery technologies to reformulate and improve existing medications, making them more effective or convenient for patients. Its business model is primarily centered on developing these products and then out-licensing them to major pharmaceutical partners, alongside offering contract research and manufacturing services. Although the company received SEBI approval for an Initial Public Offering (IPO) in 2021, it has not yet launched the issue and remains a privately held company.